JBF Capital’s Immunogen Inc IMGN Stock Holding History

JBF Capital’s Portfolio IMGN Stock Details IMGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-100,000	Closed	-$217K	–	91
2019 Q2	$217K	Buy	+100,000	New	+$236K	0.04%	52

Other funds holding IMGN

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JBF Capital's IMGN Position: Q3 2019 in Review

JBF Capital sold out of Immunogen Inc (IMGN) in Q3 2019, closing a stake of 100,000 shares — an estimated $217K sold.

JBF Capital first reported a position in IMGN in Q2 2019 and held it in 1 quarter. The position peaked at $217K in Q2 2019. 189 funds tracked by Wall St. Rank hold IMGN as of Q3 2019.

JBF Capital reported no remaining Immunogen Inc position as of Q3 2019 after selling out during the quarter.
JBF Capital sold 100,000 Immunogen Inc shares in Q3 2019, an estimated $217K.
JBF Capital first reported a position in Immunogen Inc in Q2 2019 and held it in 1 quarter.
JBF Capital's Immunogen Inc position peaked at $217K in Q2 2019.
189 funds tracked by Wall St. Rank held Immunogen Inc as of Q3 2019.

Based on JBF Capital's 13F filing for Q3 2019, filed 8 Nov 2019.